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Manual. The Efficacy Index (EI) calculating the frequency 
and patient survival of metastases to each zone was investi-
gated according to tumor location.
Results The EI was high in supraclavicular and upper 
mediastinal zones in patients with upper esophageal 
tumors, highest in upper mediastinal zone followed by 
supraclavicular and perigastric zones in patients with mid-
dle esophageal tumors, and highest in perigastric zone fol-
lowed by upper and lower mediastinal zones in patients 
with lower esophageal tumors. In patients with middle and 
lower esophageal cT1 tumors, the EIs of upper mediastinal 
and perigastric zones were higher than middle and lower 
mediastinal zones.
Conclusion The EIs of each zone were differed by tumor 
location. The extent of lymph node dissection should be 
estimated by the dissected zones and modified by the tumor 
location. Supraclavicular dissection is indispensable for 
patients with upper esophageal tumors, and recommended 
for patients with middle esophageal tumors. Upper medi-
astinal dissection is recommended for all patients with tho-
racic esophageal squamous cell carcinoma, irrespective of 
the location.
Keywords Esophageal cancer · Squamous cell 
carcinoma · Lymphadenectomy · Metastasis · Survival
Introduction
Despite recent advances in multidisciplinary approaches, 
surgical resection remains the standard treatment for poten-
tially resectable esophageal carcinoma. In addition to primary 
tumor resection, removal of all potentially involved lymph 
nodes is essential for achieving cure. In the present 7th UICC 
TNM classification [1] and the 7th AJCC Cancer Staging 
Abstract 
Background The extent of node dissection in esopha-
geal cancer surgery is usually estimated by the number of 
resected nodes, irrespective of the area of dissection. The 
efficacy of lymph node dissection by area was evaluated 
according to the location of the primary tumor.
Methods The study group comprised the 3827 patients 
who underwent R0 esophagectomy with three-field lymph 
node dissection for squamous cell carcinoma, registered in 
a nationwide registry in Japan. The areas of lymph node 
were classified into zones according to AJCC Staging 
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manual [2], the regional nodes are not varied irrespective of 
the location of the primary tumor. The extent of lymph node 
dissection in esophageal cancer surgery is estimated by the 
number of resected regional lymph nodes, irrespective of the 
area of dissection [2]. However, many surgeons accept that 
the area of nodal dissection should be modified according to 
the location of the primary tumor in an individual patient.
The purpose of this retrospective study was to evaluate 
the efficacy of lymph node dissection by the area based on 
the location of the primary tumor, calculating the frequency 
and patient survival of metastases to the area in patients 
with thoracic esophageal squamous cell carcinoma who 
underwent esophagectomy with curative intent. This study 
was based on a large, multi-institutional, nationwide regis-




A comprehensive registry of esophageal cancer in Japan 
has been maintained by the Japan Esophageal Society since 
1976. All patient data, including demographic characteristics, 
symptoms, clinical stage, treatment features, and survival 
information, were collected. Surgical features, clinical and 
pathological stage, and detailed lymph node metastatic status 
were also collected for patients who underwent surgery.
A total of 24,748 patients with primary esophageal 
tumor treated in 2004, 2005 and 2006, and 2007 and 2008 
were registered in 2011, 2012, and 2014, respectively, from 
239 institutions in Japan [3–7]. Of the 24,748 patients, 
22,667 had primary thoracic esophageal tumor, excluding 
cervical esophageal tumor and Siewert type II and type 
III esophagogastric junction cancers [8]. Of the 12,408 
patients who underwent esophagectomy, 11,136 under-
went R0 resection, and patients who underwent R1 and R2 
resections were excluded due to limited node dissection. 
Of the 11,136 patients who underwent R0 resection. 4820 
(43.3 %) patients underwent esophagectomy with three-
field lymph node dissection [9, 10]. For the purpose of 
evaluating the frequency of metastasis to all regional 
node areas precisely, only the patients who underwent 
esophagectomy with three-field lymph node dissection 
were selected. The cervical, mediastinal, and abdominal 
lymph nodes were dissected. Dissections of supraclavicu-
lar nodes and cervical paraesophageal nodes were required 
for cervical dissection by three-field dissection in the regis-
tration. Since it was based on a multi-institutional, nation-
wide registry, the selection of patients and indications for 
three-field dissection depended on each institution and each 
surgeon, and were not specified. The three-field dissection 
was performed in 60.5 % of patients with upper esophageal 
tumor, 49.5 % of patients with middle esophageal tumor, 
and 30.8 % of patients with lower esophageal tumor. It was 
performed in 36.5 % of patients with cT1 tumor and 48.2 % 
of patients with cT2-4 tumor. Of the 4820 patients who 
underwent esophagectomy with three-field lymph node dis-
section for R0 resection, information about the locations 
of pathological metastatic lymph nodes was available for 
4083 patients, and outcome evaluations were available in 
4004 patients. Of the 3956 patients excluding 48 patients 
who received definitive chemoradiotherapy and underwent 
salvage esophagectomy, 3827 patients (97 %) had squa-
mous cell carcinoma including adenosquamous carcinoma 
and basaloid squamous carcinoma, 64 patients (1.6 %) had 
adenocarcinoma, and 65 patients had other tumors includ-
ing undifferentiated tumor, carcinosarcoma and malignant 
melanoma. The total study group comprised 3827 patients 
who underwent R0 resection and esophagectomy with 
three-field lymph node dissection for squamous cell carci-
noma from 155 institutions (Fig. 1).
Tumor classification
Clinical stages for all patients were recorded according 
to the 6th edition of the UICC TNM Classification [11]. 
Pathological stages for all patients were re-assessed accord-
ing to the 7th edition of the UICC TNM Classification [1]. 
The thoracic esophagus was divided into three anatomical 
subsites: upper, middle, and lower. The tumor location is 
regarded as the point of deepest tumor invasion according 
to the Japanese Classification [12], which in clinical prac-
tice is the epicenter of the tumor.


















Fig. 1  Patient disposition chart
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The areas of lymph node metastasis were recorded 
according to the lymph node stations adopted by the Japa-
nese Classification [12]. There are some differences in the 
definition of lymph node stations between the Japanese 
Classification [12] and AJCC Staging Manual [2] (Table 1). 
This difference in the anatomical definition of each lymph 
node station might have influenced the nodal categoriza-
tion. However, with the database collected, there was no 
way to reasonably reconcile or amend such differences. 
So, lymph node stations were classified into lymph node 
zones according to the map in AJCC Staging Manual [2] 
(Table 1). The middle mediastinal zone and the lower medi-
astinal zone were divided by caudal margin of the inferior 
pulmonary vein.
Method of analysis
To evaluate the efficacy of nodal dissection at each zone, 
the efficacy index (EI) was calculated by multiplying the 
frequency (%) of metastases to a zone and the 5-year sur-
vival rate (%) of patients with metastases to that zone, and 
then dividing by 100 [13–15]. The EI was investigated 
according to tumor location. The EI was also determined 
by clinical T factor: cT1 and cT2-4. Survival rates were 
constructed using the Kaplan–Meier method. Statistical 
analysis was performed using the SPSS Statistics Software 
Package (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics and findings are listed in Table 2. 
The location of the tumors was the upper esophagus in 629 
patients (16.4 %), the middle esophagus in 2215 (57.9 %), 
and the lower esophagus in 983 (25.7 %).
Preoperative neoadjuvant chemoradiotherapy was 
administered to 238 patients (6.2 %), 515 patients (13.5 %) 
received preoperative chemotherapy, and 3 patients (0.1 %) 
received preoperative radiotherapy. Preoperative therapy 
was under clinical study [16] and not standard for esopha-
geal cancer in Japan during the registration period. The 
selection of patients, indications, and therapeutic approach 
to preoperative therapy depended on each institution and 
were not specified.
Table 1  Node zones
Node zone Station number (JES) Name of node station (JES) Station number (AJCC) Name of node station (AJCC)
Supraclavicular 104R Right supraclavicular 1 Supraclavicular
104L Right supraclavicular 1 Supraclavicular
101R Right cervical paraesophageal (Cervical paraesophageal)
101L Right cervical paraesophageal (Cervical paraesophageal)
Upper mediastinal 105 Upper paraesophageal 3p Posterior mediastinal
106pre Pretracheal 2R Right upper paratracheal
106recR Right recurrent nerve 2R Right upper paratracheal
106recL Right recurrent nerve 2L Left upper paratracheal
106tbR Right tracheobronchial 4R Right lower paratracheal
106tbL Right tracheobronchial 4L Left lower paratracheal
Middle mediastinal 107 Subcarinal 7 Subcarinal
108 Middle paraesophageal 8 m Middle paraesophageal
109R Right main bronchus 10R Right tracheobronchial
109L Left main bronchus 10L Left tracheobronchial
Lower mediastinal 110 Lower paraesophageal 8 l Lower paraesophageal
111 Supradiaphragmatic 15 Diaphragmatic
112 Posterior mediastinum 9 Pulmonary ligament
Perigastric 1 Right cardiac 16 Paracardial
2 Left cardiac 16 Paracardial
3 Lesser curvature
7 Left gastric artery 17 Left gastric artery
Celiac 9 Celiac 20 Celiac
8 Common hepatic artery 18 Common hepatic
11 Splenic artery 19 Splenic
19 Infradiaphragmatic
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The 30-day operative mortality rate was 0.9 % (33 
patients) and 90-day mortality was 1.8 % (69 patients). The 
5-year survival rate for all patients was 57.5 %.
The frequency of metastasis, the 5-year survival rate of 
patients with metastases, and the EI of each zone are pre-
sented according to tumor location in Table 3. The frequency 
of metastasis and the EI of each zone were different by tumor 
locations. In patients with upper esophageal tumors, the EIs 
of the supraclavicular zone and the upper mediastinal zone 
were high. In contrast, those of the middle mediastinal, lower 
mediastinal and perigastric zones were low. In patients with 
middle esophageal tumors, the EI of the upper mediastinal 
zone was the highest, followed by those of supraclavicular 
zone and perigastric zones. In patients with lower esophageal 
tumors, the EI of perigastric zone was the highest, followed 
by those of upper mediastinal and lower mediastinal zones. 
The EIs of celiac zone were the lowest among all the zones 
in patients with thoracic squamous cell carcinoma. Differ-
ences of the EIs between zones mostly depended on differ-
ence of the frequency of metastasis to zones. Differences of 
the 5-year survival rates of patients with metastases between 
zones were less.
The frequency of metastasis, the 5-year survival rate 
of patients with metastases, and the EIs of each zone 
in patients with cT1 tumor are presented in Table 4. In 
patients with upper esophageal cT1 tumors, the EI of the 
upper mediastinal zone was highest. However, in patients 
Table 2  Patients’ characteristics and tumor findings
Characteristic or finding No. (%)
Median age (range), year 63.0 (30–85)
Sex
 Male 3293 (86.0 %)
 Female 534 (14.0 %)
Tumor location
 Upper 983 (16.4 %)
 Middle 2215 (57.9 %)
 Lower 629 (25.7 %)
Preoperative therapy
 Chemotherapy 515 (13.5 %)
 Chemoradiotherapy 238 (6.2 %)
 Radiotherapy 3 (0.1 %)
 None 3071 (80.2 %)
Clinical T classification
 T1 1160 (30.3 %)
 T2 701 (18.3 %)
 T3 1810 (47.3 %)
 T4 156 (4.1 %)
Pathologic positive node number (including supraclavicular node)
 N0 1616 (42.2 %)
 N(1–2) 843 (22.0 %)
 N(3–6) 903 (23.6 %)
 N(7–) 465 (12.2 %)
Table 3  The frequency of metastasis, the 5-year survival rate of patients with metastases, and the EI of each zone according to tumor location 















































27 4.3 33.1 1.4 254 11.5 33.5 3.9 242 24.6 34.2 8.4
Perigastric 
zone
62 9.9 31.1 3.1 618 27.9 33.2 9.3 479 48.7 36.5 17.8
Celiac 
zone
5 0.8 0.0 0.0 89 4.0 26.1 1.0 104 10.6 27.0 2.9
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with middle and lower esophageal cT1 tumors, the EIs of 
the middle and lower mediastinal zones were lower than 
those of the upper mediastinal and perigastric zones. In 22 
patients with lower esophageal cT1 tumors and metastasis 
to the supraclavicular zone, 9 patients had the proximal 
margin of the tumor in the middle esophagus. In 27 patients 
with lower esophageal cT1 tumors and metastasis to the 
upper mediastinal zone, 14 patients had the proximal mar-
gin of the tumor in the middle esophagus.
The frequency of metastasis, the 5-year survival rate of 
patients with metastases, and the EIs of each zone in patients 
with cT2-4 tumors are presented in Table 5. In patients with 
middle esophageal cT2-4 tumors, frequency of lymph node 
metastasis and the EI of the middle mediastinal zone was 
increased dramatically compared with patients with cT1 
tumors, but still lower than those of the upper mediastinal 
and perigastric zones. In patients with lower esophageal 
cT2-4 tumors, the EI of the upper mediastinal zones was as 
high as that of the lower mediastinal zones.
Discussion
The present study showed that the efficacies of node dissec-
tion differed by zone of lymph node. Many previous studies 
demonstrated that the number of lymph nodes removed is 
an independent predictor of survival after esophagectomy 
for cancer [17–22]. The extent of lymph node dissection 
in esophageal cancer surgery was estimated by the number 
of resected regional lymph nodes. In the present 7th UICC 
TNM Classification, it is recommended that histological 
examination of a regional lymphadenectomy specimen ordi-
narily include 7 or more lymph nodes [1]. The 7th AJCC 
staging manual recommends that, for pT1, approximately 
10 nodes must be resected to maximize survival; for pT2, 20 
nodes; and for pT3 or pT4, 30 nodes or more [2], based on 
the data of the worldwide esophageal cancer collaboration 
[22]. In NCCN guideline, in patients undergoing esophagec-
tomy without induction chemoradiation, at least 15 lymph 
nodes should be removed to achieve adequate nodal stag-
ing [23]. However, when only the node zones with low EI 
are dissected, and those with high EI are not dissected, the 
efficacy of node dissection is low, even more than 20 nodes 
are dissected. Thus, the effective extent of node dissection 
should be modified by the EIs of node zones.
EIs of each node zone were differed by tumor location. 
The zones for dissection should be modified according to 
the location of the tumor. For upper esophageal tumors, 
the upper mediastinal zone had the highest EI and is the 
most important dissection target. The EI of supraclavicu-
lar zone was also high and supraclavicular node dissection 
is indispensable for patients with upper esophageal tumor. 
Supraclavicular nodes should be classified as regional 
nodes for tumors in the upper esophagus. In patients with 
Table 4  The frequency of metastasis, the 5-year survival rate of patients with metastases, and the EI of each zone according to tumor location 






















































8 3.8 15.0 0.6 76 10.1 53.9 5.4 34 17.3 45.2 7.8
Celiac 
zone
0 0.0 11 1.5 36.4 0.5 5 2.5
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tumor in the middle esophagus, upper mediastinal zone had 
the highest EI followed by perigastric and supraclavicular 
zones. For patients with tumor in the middle esophagus, the 
most common type of esophageal tumor in Asia, not only 
mediastinal and abdominal, but also cervical dissection 
by the three-field approach is recommended. Patients with 
tumor in the lower esophagus had the highest EI in perigas-
tric zone. However, the EI of upper mediastinal zone was 
as high as that of lower mediastinal zone. Upper mediasti-
nal dissection is recommended for all patients with thoracic 
esophageal squamous cell carcinoma, irrespective of the 
location.
The present study showed that the frequency of metas-
tasis and the EI did not reflect the anatomical distance 
from the primary tumor, but rather the lymphatic drain-
age system reported previously [24, 25]. Even with tumors 
located in the middle and lower esophagus, lymphatic 
metastasis was frequent in the upper mediastinal and per-
igastric zones. The conventional hypothesis is that tumor 
cells involve the nearby nodes first, then spread to nodes a 
little further, and finally reach distant nodes. The extent of 
node dissection has been estimated by anatomical distance 
from the primary tumor to the dissected node area. How-
ever, in patients with middle and lower esophageal cT1 
tumors, the EIs of the middle and lower mediastinal zone 
were lower than those of upper mediastinal zone and per-
igastric zone. Therefor extent of dissection in patients with 
cT1 tumors should be not tailored according to the ana-
tomical distance from the tumor, but according to the EI.
Many patients with lower esophageal cT1 tumors and 
the proximal margin of the tumor in the middle esopha-
gus had metastasis to the supraclavicular zone and the 
upper mediastinal zone. It suggests that the proximal 
nodal spread to the supraclavicular and upper mediasti-
nal nodes is reflect to the location of proximal margin of 
the tumor. The attention to the proximal margin of tumor 
should be paid in planning the extend of node dissection. 
The proximal margin of squamous cell carcinoma tends 
to be more proximal than those of adenocarcinoma. Supr-
aclavicular and upper mediastinal node metastasis are not 
neglected.
In this study, lymph node stations were classified into 
lymph node zones according to the map in AJCC Staging 
Manual. In surgical dissection and in identification and 
labeling during pathological examination of specific lymph 
node, and also in planning of irradiation field, lymph node 
zones are more practical than small neighboring lymph 
node stations.
The present study was based on patients with squamous 
cell carcinoma, and patients with adenocarcinoma were not 
included. However, in Asian patients, including Japanese 
patients, squamous cell carcinoma remains the predominant 
histological cell type of esophageal cancer, and more than 
half of tumors locates in the upper and middle esophagus.
Table 5  The frequency of metastasis, the 5-year survival rate of patients with metastases, and the EI of each zone according to tumor location 






















































54 12.9 33.8 4.4 542 37.0 30.3 11.2 445 56.6 35.7 20.2
Celiac  
zone
5 1.2 0.0 0.0 78 5.3 24.6 1.3 99 12.6 25.3 3.2
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In conclusion, the EIs of each zone were differed by 
tumor location. The extent of lymph node dissection should 
be estimated by the dissected lymph node zones and modi-
fied by the tumor location. Supraclavicular dissection is 
indispensable for patients with upper esophageal tumors 
and recommended for patients with middle esophageal 
tumors. Upper mediastinal dissection is recommended for 
all patients with thoracic esophageal squamous cell carci-
noma, irrespective of the location.
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